Longitudinal Early-onset Alzheimer's Disease Study (LEADS)
-
- STATUS
- Not Recruiting
Summary
This is a non-randomized, natural history, non-treatment study. Assessments are to be collected at baseline and Year 1 (both Early Onset Alzheimer?s Disease (EOAD) and Cognitively Normal (CN) cohorts) and Year 2 (EOAD cohort only).
The primary objectives are to collect longitudinal assessments and biomarker data for 400 EOAD and 100 CN participants; compare baseline and longitudinal cognitive and functional characteristics, between EOAD and CN, and EOAD and Late Onset Alzheimer?s Diseases (LOAD) from the Alzheimer?s Disease Neuroimaging Initiative (ADNI); and study the associations of longitudinal clinical and cognitive assessments with multimodal imaging and biofluid markers that capture different elements of the AD pathophysiological cascade.
The scientific aims are to compare the baseline and longitudinal cognitive and functional characteristics of EOAD compared to LOAD and identify optimal outcome measures for clinical trials; compare baseline and longitudinal MRI, amyloid PET, tau PET and cerebrospinal fluid measures between EOAD and LOAD and identify optimal imaging outcome measures for clinical trials; investigate the influence of APOE genotype on baseline and longitudinal imaging biomarkers and clinical phenotype in EOAD; and characterize genetic contributions to EOAD and obtain annually an array of uniformly collected biospecimens for future biomarker development.
Description
This is a non-randomized, natural history, non-treatment study. Assessments are to be collected at baseline and Year 1 (both Early Onset Alzheimer?s Disease (EOAD) and Cognitively Normal (CN) cohorts) and Year 2 (EOAD cohort only).
The primary objectives are to collect longitudinal assessments and biomarker data for 400 EOAD and 100 CN participants; compare baseline and longitudinal cognitive and functional characteristics, between EOAD and CN, and EOAD and Late Onset Alzheimer?s Diseases (LOAD) from the Alzheimer?s Disease Neuroimaging Initiative (ADNI); and study the associations of longitudinal clinical and cognitive assessments with multimodal imaging and biofluid markers that capture different elements of the AD pathophysiological cascade.
The scientific aims are to compare the baseline and longitudinal cognitive and functional characteristics of EOAD compared to LOAD and identify optimal outcome measures for clinical trials; compare baseline and longitudinal MRI, amyloid PET, tau PET and cerebrospinal fluid measures between EOAD and LOAD and identify optimal imaging outcome measures for clinical trials; investigate the influence of APOE genotype on baseline and longitudinal imaging biomarkers and clinical phenotype in EOAD; and characterize genetic contributions to EOAD and obtain annually an array of uniformly collected biospecimens for future biomarker development.
Details
| Condition | Alzheimer's Disease |
|---|---|
| Age | 100years or below |
| Clinical Study Identifier | TX8671 |
| Last Modified on | 19 February 2024 |
Similar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.